Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR England slips further off-track for smokefree 2030 target December 29, 2022 Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... October 19, 2021 A Penny for Your Thoughts August 17, 2021 Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer May 15, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma A Remarkable Group of Patients with Haematological Disorders with No or... Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her... EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of...
